-
公开(公告)号:US20050049310A1
公开(公告)日:2005-03-03
申请号:US10913882
申请日:2004-08-06
申请人: Adnan Mjalli , Guoxiang Huang , Murty Arimilli , Thomas Yokum , Jeff Zhu
发明人: Adnan Mjalli , Guoxiang Huang , Murty Arimilli , Thomas Yokum , Jeff Zhu
IPC分类号: A61P31/12 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C271/20 , C07C311/08 , C07C311/09 , C07C311/21 , C07C311/44 , C07C317/32 , C07C323/36 , C07D295/155 , A61K31/195 , A61K31/137 , A61K31/15
CPC分类号: C07D295/155 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C271/20 , C07C311/08 , C07C311/09 , C07C311/21 , C07C311/44 , C07C317/32 , C07C323/36 , C07C2601/08
摘要: This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and/or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.
摘要翻译: 本发明提供了本文所述的式(I)的芳基和杂芳基化合物及其制备方法。 还提供了用式(I)的化合物制备的药物组合物和制备这些组合物的方法。 式(I)的化合物可以激活促红细胞生成素受体,因此可用于诱导红细胞生成。 式(I)化合物和包含式(I)化合物的组合物可用于各种应用,包括至少部分地由EPO生产缺陷(或低效)引起的疾病的管理,治疗和/或控制,相对于 血红蛋白水平。